Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 3/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | CETP | P11597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26199833 | 0.84 | CHRM2 (0.43) | CHRM2CHRM1CHRM3PREP | |
| SCHEMBL26196651 | 0.84 | CHRM2 (0.43) | CHRM2CHRM1CHRM3PREP | |
| SCHEMBL29428649 | 0.84 | CHRM2 (0.43) | CHRM2CHRM1CHRM3PREP | |
| SCHEMBL27302062 | 0.84 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL29428536 | 0.82 | CHRM2 (0.48) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL29428683 | 0.82 | CHRM2 (0.48) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL26196638 | 0.77 | CHRM2 (0.47) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL25324203 | 0.77 | CHRM2 (0.47) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL29428638 | 0.76 | CHRM2 (0.50) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL29428754 | 0.76 | CHRM2 (0.50) | CHRM2CHRM1CHRM3PREPNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4626554-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | Tiger Biotherapeutics Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12168058-B2 | Glutarimide-containing KRAS-mutant degrader compounds and uses thereof | Tiger Biotherapeutics, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024118960-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-11964989-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2024-04-23 | — | — | US | disclosed |
| CN-114615981-B | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230077225-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. | 2023-03-09 | — | — | US | disclosed |
| US-11453683-B1 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2022-09-27 | — | — | US | disclosed |
| EP-4021444-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-114615981-A | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| WO-2021041671-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | CHRM2 4828/4885CHRM1 4843/4885CHRM3 4866/4885 |
| US-20230077225-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | CHRM2 4884/4885CHRM1 4881/4885CHRM3 4883/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | CHRM2 4858/4885CHRM1 4828/4885CHRM3 4882/4885 |
| US-12168058-B2 | Glutarimide-containing KRAS-mutant degrader compounds and uses thereof | KRAS, VHL, HRAS | CHRM2 4828/4885CHRM1 4843/4885CHRM3 4866/4885 |
| US-11964989-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | CHRM2 4882/4885CHRM1 4881/4885CHRM3 4884/4885 |
| US-11453683-B1 | KRas G12D inhibitors | KRAS, NRAS, HRAS | CHRM2 4882/4885CHRM1 4881/4885CHRM3 4884/4885 |
| US-20240309020-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | CHRM2 4884/4885CHRM1 4881/4885CHRM3 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.